Information Provided By:
Fly News Breaks for April 3, 2017
ACOR
Apr 3, 2017 | 08:19 EDT
After the District Court decision to invalidate four of five Acorda's Ampyra patents, Leerink analyst Paul Matteis says it shifts the investment conversation toward an NDA filing, FDA review and launch of CVT-301 in the backdrop of what could represent a "fairly aggressive" restructuring/contingency plan. The analyst believes the 2018-2020 Acorda revenue/EPS consensus estimates now look "far too high" and are likely to adjust.
News For ACOR From the Last 2 Days
There are no results for your query ACOR
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.